Drug Profile
CM 101
Alternative Names: GBS toxin; ZD 0101Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Vanderbilt University
- Developer TumorEnd
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Cancer; Craniocerebral trauma; Psoriasis; Reperfusion injury; Rheumatoid arthritis; Spinal cord injuries; Wounds
Most Recent Events
- 27 Jul 2006 No development reported - Phase-I for Cancer in USA (IV)
- 27 Jul 2006 No development reported - Phase-I for Spinal cord injuries in USA (IV)
- 27 Jul 2006 No development reported - Preclinical for Head injuries in USA (unspecified route)